Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

@article{Serve2013SorafenibIC,
  title={Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.},
  author={Hubert Serve and Utz Krug and Ruth Wagner and Maria Cristina Sauerland and A. Heinecke and Uta Brunnberg and Markus Schaich and Oliver G Ottmann and Justus Duyster and Hannes Wandt and Thomas Fischer and Aristoteles Giagounidis and Andreas Neubauer and Albrecht Reichle and Walter Erich Aulitzky and Richard Noppeney and Igor Wolfgang Blau and Volker Kunzmann and Reingard Stuhlmann and Alwin Kraemer and K S Kreuzer and Christian Brandts and Bj{\"o}rn Steffen and Christian Thiede and Carsten M{\"u}ller-Tidow and Gerhard Ehninger and Wolfgang E. Berdel},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 25},
  pages={3110-8}
}
PURPOSE The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML. PATIENTS AND METHODS All patients received standard cytarabine and daunorubicin induction (7+3 regimen) and up to two cycles of intermediate-dose cytarabine consolidation. Two… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 19 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 90 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Similar Papers

Loading similar papers…